Ligand Pharmaceuticals acquires Xoma Royalty for $740 million
Here's what it means for you.
This acquisition could reshape Ligand's position in the competitive biotech landscape.
What happened
Ligand Pharmaceuticals is acquiring Xoma for nearly $740 million.
The Context
- Investment Focus: Both Ligand and Xoma are known for investing in drug development and collecting royalties from successful sales.
- Strategic Expansion: The acquisition is part of Ligand's strategy to expand its influence in the biotech industry.
- Industry Trends: This deal reflects ongoing consolidation trends in the pharmaceutical and biotech sectors.
Takeaway
The acquisition could position Ligand for greater success in the competitive biotech landscape.
Brokerage upgrades/downgrades, price-target changes, and fresh coverage that move single names and sectors.
"Handy for tracking sentiment shifts from the sell side and consensus drift."
— A47 Editor
BofA raises Ligand Pharma stock price target on XOMA acquisition
Bank of America (BofA) has raised its stock price target for Ligand Pharmaceuticals following the company's recent acquisition of XOMA. This adjustment reflects BofA's analysis of Ligand's strategic moves and market potential.
Public health, medical research, healthcare policy, and pharmaceutical developments.
"Dow Jones is a major financial news provider with a professional tone and broad coverage, including specialized health-sector reporting."
— A47 Editor
Ligand Pharmaceuticals said it has reached a deal to acquire Xoma Royalty, a company that invests in a range of biotech firms, for around $740 million
Ligand Pharmaceuticals has announced a deal to acquire Xoma Royalty for approximately $740 million. Xoma Royalty is recognized for its investments in various biotech firms, focusing on drugs during their development phases and collecting royalties fr...
Markets desk coverage, trading insights, and investor updates.
"WSJ’s markets reporting provides in-depth analysis and context for investors."
— A47 Editor
Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million
Ligand Pharmaceuticals has announced its acquisition of Xoma for nearly $740 million, marking a significant move in the pharmaceutical market. Both companies are recognized as royalty aggregators, investing in drug development and earning royalties f...
U.S. business news, corporate developments, and economy.
"The Wall Street Journal is respected for deep financial and economic reporting with a center-right editorial perspective."
— A47 Editor
Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million
Ligand Pharmaceuticals has announced its acquisition of Xoma for nearly $740 million, a significant move in the pharmaceutical market as both companies are recognized as royalty aggregators that invest in drug development and earn royalties from succ...